Zurich Cantonal Bank’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-17,623
| Closed | -$416K | – | 2745 |
|
|
2023
Q4 | $416K | Sell |
17,623
-252
| -1% | -$4.49K | ﹤0.01% | 1623 |
|
|
2023
Q3 | $267K | Sell |
17,875
-810
| -4% | -$10.7K | ﹤0.01% | 1789 |
|
|
2023
Q2 | $205K | Buy |
18,685
+3,536
| +23% | +$32.9K | ﹤0.01% | 1911 |
|
|
2023
Q1 | $132K | Buy |
+15,149
| New | +$121K | ﹤0.01% | 2119 |
|
|
2021
Q2 | – | Sell |
-5,635
| Closed | -$26K | – | 2624 |
|
|
2021
Q1 | $26K | Hold |
5,635
| – | – | ﹤0.01% | 2508 |
|
|
2020
Q4 | $32K | Buy |
+5,635
| New | +$42.7K | ﹤0.01% | 2532 |
|
|
2020
Q2 | – | Sell |
-4,015
| Closed | -$6K | – | 2613 |
|
|
2020
Q1 | $6K | Hold |
4,015
| – | – | ﹤0.01% | 2547 |
|
|
2019
Q4 | $8K | Hold |
4,015
| – | – | ﹤0.01% | 2577 |
|
|
2019
Q3 | $21K | Hold |
4,015
| – | – | ﹤0.01% | 2451 |
|
|
2019
Q2 | $29K | Hold |
4,015
| – | – | ﹤0.01% | 2338 |
|
|
2019
Q1 | $53K | Sell |
4,015
-1,312
| -25% | -$14K | ﹤0.01% | 1964 |
|
|
2018
Q4 | $42K | Hold |
5,327
| – | – | ﹤0.01% | 2140 |
|
|
2018
Q3 | $59K | Hold |
5,327
| – | – | ﹤0.01% | 2063 |
|
|
2018
Q2 | $71K | Buy |
+5,327
| New | +$66.7K | ﹤0.01% | 1893 |
|
Other funds holding CBAY
Zurich Cantonal Bank's CBAY Position: Q1 2024 in Review
Zurich Cantonal Bank sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 17,623 shares — an estimated $416K sold.
Zurich Cantonal Bank first reported a position in CBAY in Q2 2018 and held it in 14 quarters. The position peaked at $416K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Zurich Cantonal Bank reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Zurich Cantonal Bank sold 17,623 Cymabay Therapeutics shares in Q1 2024, an estimated $416K.
- Zurich Cantonal Bank first reported a position in Cymabay Therapeutics in Q2 2018 and held it in 14 quarters.
- Zurich Cantonal Bank's Cymabay Therapeutics position peaked at $416K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Zurich Cantonal Bank's 13F filing for Q1 2024, filed 25 Apr 2024.